According a review (Inflamm Bowel Dis 2014; 20: 1862-69) of 5 studies with 1216 patients, “the use of anti-TNFα therapy does not seem to increase the risk of unfavorable pregnancy outcomes among women with IBD, although the optimal timing of therapy through pregnancy and the postpartum period was not assessed.”
Other important points:
- “Current recommendations suggest that anti-TNFα therapies be continued during the first 2 trimesters of pregnancy.” Withholding of infliximab and adalimumab during the third trimester is due to concerns of increased drug levels in infants.
- Live virus vaccination should “be avoided for the first 6 months in children who had exposure to anti-TNFα therapies in utero.”
Related blog posts: